Craig C Hofmeister MD

PubMed

• Early CD4+ T cell proliferation and chronic T cell engagement impact myeloma outcomes following T cell engager therapy.
  Alyssa M Duffy, Anshika Goenka, Maryam I Azeem, Azmain Taz, Sayalee V Potdar
  The Journal of Clinical Investigation. 2025-10-01
• Infection risk in 158 patients with relapsed/refractory multiple myeloma treated with bispecific antibodies: a single-center experience.
  Lorenzo Cani, Sara A Scott, Danielle Roberts, Nisha S Joseph, Craig C Hofmeister
  Haematologica. 2025-09-04
• 1 citations
  Feasibility and Safety of Outpatient Model for Administration of Bispecific Antibodies: Proceedings from an International Myeloma Society 21st Annual Meeting Oral Abst...
  Sara A Scott, Danielle L Roberts, Vikas A Gupta, Nisha S Joseph, Craig C Hofmeister
  Clinical Lymphoma, Myeloma & Leukemia. 2025-09-01

Journal Articles

• Twice‐Weekly Ixazomib in Combination with Lenalidomide‐Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma  
  Myo Htut, Michaela Liedtke, Stephen D Smith, Craig C Hofmeister, Rachid Baz, Paul G Richardson, Cara A Rosenbaum, David H Vesole, Ajai Chari, Jesus G Berdeja, Noopur Raje, British Journal of Haematology
• Evidence Does Not Support Clinically Significant Lenalidomide-CCI-779 Interaction via P-Glycoprotein Reply  
  Hofmeister,CC; Yang,X; Phelps,MA, Journal of Clinical Oncology, 1/1/2012
• Evaluation of pulmonary infiltrates in post stem cell transplant patients  
  Scaglione S, Hofmeister CC, Stiff PJ, Hematology, 12/1/2005
• Mucosal protection by cytokines  
  Hofmeister CC, Stiff PJ, Current Hematology Reports, 11/1/2005
• Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development  
  Pichiorri F, Suh SS, Rocci A, De Luca L, Taccioli C, Santhanam R, Zhou W, Benson DM, Hofmeister CC, Alder H, Garofalo M, Di Leva G, Volinia S, Lin HJ, Perrotti D, Kueh..., Cancer Cell
• Join now to see all

Abstracts/Posters

• Ixazomib or Lenalidomide Maintenance Following Autologous Stem Cell Transplantation and Ixazomib, Lenalidomide, and Dexamethasone (IRD) Consolidation in Patients with ...
  Craig C Hofmeister, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Proteasome Inhibitors Impair the Innate Antiviral Immune Response and Potentiate Pelareorep-Based Viral Therapy in Multiple Myeloma
  Craig C Hofmeister, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrang...
  Craig C Hofmeister, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Comparative Analysis of Immune Reconstitution in HIV-Positive Recipients of Allogeneic and Autologous Stem Cell Transplant on the BMT CTN 0903/AMC-080 and BMT CTN 0803...
  Craig C Hofmeister, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all

Lectures

• Lenalidomide and Vorinostat Maintenance after Autologous Transplant in Multiple Myeloma- Long Term Follow-up 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Updated Results from the Phase 2 Centaurus Study of Daratumumab (DARA) Monotherapy in Patients with Intermediate-Risk or High-Risk Smoldering Multiple Myeloma (SMM) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Outcomes of Myeloma Patients with Deletion 1p Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) Therapy 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Ixazomib-Lenalidomide-Dexamethasone (IRd) Consolidation Following Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Large Multi... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Join now to see all